Study of LVGN6051 (CD137 Agonist Antibody) in Advanced or Metastatic Malignancy

Inclusion Criteria: * Males or females aged ≥ 18 years. * Ability to understand and willingness to sign a written informed consent document. * Patients must have a histologically or cytologically confirmed metastatic or unresectable malignancy. * Estimated life expectancy, in the judgment of the Investigator, of at least 90 days. * Adequate bone marrow, liver, and renal functions. * Men and women of childbearing potential must agree to take highly effective contraceptive methods. * Patients should recover from all reversible AEs of previous anticancer therapies to baseline. Exclusion Criteria: * Receipt of CD137 and or PD-1 antibodies. * Receipt of systemic anticancer therapy within 5 half-lives of the first dose of study treatment. * Known active CNS metastasis and/or carcinomatous meningitis. * Has received a live-virus vaccine within 30 days. * Has had a Grade ≥ 3 allergic reaction to treatment with a monoclonal antibody. * Abnormality of QT interval or syndrome. * Patients with history of Grade ≥ 3 immune-related AEs (irAEs) or irAE. * Patients who are receiving an immunologically-based treatment for any reason. * Active or chronic autoimmune disease that has required systemic treatment in the past 2 years or who are receiving systemic therapy for an autoimmune or inflammatory disease. * Has a clinically significant cardiac condition, including unstable angina, acute myocardial infarction within 6 months. * Has an active infection requiring intravenous (i.v.) anti-infectives within 14 days before the first dose of study treatment. * Tested positive of HIV or HBV or HCV. * Female patients who are pregnant or breastfeeding. * Any evidence of severe or uncontrolled systemic disease. * Has previously had a CAR-T therapy, or stem cell or bone marrow or solid organ transplant.